



21 July 2020

Circular 022/20

Semaglutide (Ozempic®)

Dear Pharmacist,

I refer to previous correspondence in relation to Liraglutide (Victoza®) and reimbursement under Community Drug Schemes (Circular 45/19). As semaglutide (Ozempic®) is indicated for the treatment of Type II Diabetes Mellitus in the same manner as Victoza®, patients are entitled to be registered under the Long Term Illness (LTI) Scheme to enable them to obtain this product free of charge. The form can be downloaded at <https://www2.hse.ie/file-library/long-term-illness/long-term-illness-scheme-application-form.pdf>.

Therefore, **effective 1st August 2020**, reimbursement will be confined to those persons with full GMS and LTI eligibility. Reimbursement of Ozempic® (GMS codes 33700, 33701 and 33702) will not be made available under the Drugs Payment Scheme (DPS) from this date.

Reimbursement support is available for the licensed indication and dosage only. Therefore, one pack of either the 0.25 mg / 0.5 mg / 1 mg strength provides a 4 weeks supply. The facility is available to pharmacies for 13 dispensing's' in a rolling 12 months to accommodate the shortfall.

Yours faithfully,

Shaun Flanagan
Primary Care Eligibility and Reimbursement